

Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Tripaydonis, A;Conyers, R;Elliott, DA

Title:

Pediatric Anthracycline-Induced Cardiotoxicity: Mechanisms, Pharmacogenomics, and Pluripotent Stem-Cell Modeling

Date:

2019-03-01

Citation:

Tripaydonis, A., Conyers, R. & Elliott, D. A. (2019). Pediatric Anthracycline-Induced Cardiotoxicity: Mechanisms, Pharmacogenomics, and Pluripotent Stem-Cell Modeling. *Clinical Pharmacology and Therapeutics*, 105 (3), pp.614-624. <https://doi.org/10.1002/cpt.1311>.

Persistent Link:

<https://hdl.handle.net/11343/250236>

License:

[CC BY-NC](#)

Pediatric Anthracycline-Induced Cardiotoxicity: Mechanisms, Pharmacogenomics, and Pluripotent Stem-Cell Modeling

Anne Tripaydonis^{1,2}, Rachel Conyers^{1,2,3,†} and David A. Elliott^{1,2,†}

Anthracycline-induced cardiotoxicity (ACT) is a severe adverse drug reaction for a subset of children treated with anthracyclines as part of chemotherapy protocols. The identification of genetic markers associated with increased ACT susceptibility has clinical significance toward improving patient care and our understanding of the molecular mechanisms involved in ACT. Human-induced pluripotent stem cell-derived cardiomyocytes represent a novel approach to determine the pharmacogenomics of ACT and guide the development of genetic screening tests.

THE ANTHRACYCLINES

The anthracyclines are a potent class of chemotherapy agent used widely in the treatment of childhood cancers. Following their introduction to clinical practice in the early 1960s and the increased international collaboration among clinical trial centers since, major advances in survival outcomes for children with cancer have been achieved. According to survivorship statistics from the United States in 2016, overall 5-year survival rates for all childhood cancers have risen from 58% for those diagnosed between 1975 and 1977 to 83% for children diagnosed between 2005 and 2011.¹ Similarly, in Australia, 5-year survival rates for all childhood cancers have risen from 72% for those diagnosed between 1983 and 1992 to 84% for children diagnosed between 2003 and 2012.² Owing to their effectiveness, anthracyclines are now included in over 50% of all paediatric chemotherapy regimens.³

Today, there are five different anthracyclines approved for use as chemotherapeutics. They are used in pediatric settings for the treatment of hematopoietic malignancies and solid tumors, including neuroblastoma, nephroblastoma, osteosarcoma, and Ewing's sarcoma. Their chemical structures are shown in **Figure 1**. Daunorubicin and doxorubicin are very similar compounds, the only difference being the primary chain of doxorubicin terminates with a hydroxyl group rather than the methyl group in daunorubicin. The second generation analog epirubicin is an epimer of doxorubicin with a shorter half-life and reported reduced cardiotoxic effects.^{4,5} Idarubicin is derived from daunorubicin and lacks the 4-methoxy group on ring D making it more lipophilic than its parent compound. Structurally related to the anthracyclines, mitoxantrone is an anthracenedione that is used in combination therapy for the treatment of acute myeloid leukemia in pediatric patients. All types of anthracyclines have been linked to the development of anthracycline-induced cardiotoxicity (ACT). Although the precise molecular mechanism for ACT remains unknown, several theories exist to describe its pathogenesis.

ACT

The therapeutic use of anthracyclines is complicated by the adverse drug reaction of cardiotoxicity. The severity of ACT is variable, ranging from asymptomatic cardiac dysfunction evidenced by echocardiogram to the development of cardiomyopathy and congestive heart failure, which affects 57% and 16% of children, respectively, postanthracycline exposure.⁶ Risk factors for ACT include younger age, female sex, higher cumulative anthracycline dose, and concomitant radiotherapy to the mediastinum.⁷ One in ten children exposed to cumulative anthracycline doses > 300 mg/m² develop anthracycline-induced congestive heart failure,⁸ which is often refractive to medical therapy and associated with a poor prognosis.⁹ ACT can have an early onset, defined as developing within 1 year of treatment, or a late onset, with increasing cumulative incidence up to 30 years posttreatment.¹⁰ Susceptibility for the development of ACT has been suggested to have a genetic basis. Many studies have identified associations between ACT and polymorphisms of genes that can be grouped into various mechanistic pathways. Among these genes are *RARG*, encoding the retinoic acid receptor- γ involved in DNA damage¹¹; *ABCC5*, an ATP cassette binding transporter¹²; *SLC28A3*, a sodium-coupled nucleoside transporter involved in transport of antineoplastic drugs¹³; and *CBR3*, a carbonyl reductase that metabolizes the anthracycline doxorubicin.¹⁴ Currently, predicting which patients will develop ACT is not possible. However, in 2016, a breakthrough study identified that human-induced pluripotent stem cells-derived cardiomyocytes (hiPSC-CMs) from patients with breast cancer exposed to anthracyclines were able to recapitulate individual patients' sensitivity to ACT at a cellular level.¹⁵ Exposure to anthracycline hiPSC-CMs from patients with ACT displayed decreased cell viability, increased reactive oxygen species (ROS) production, impaired calcium handling, and mitochondrial dysfunction. Thus,

¹Murdoch Childrens Research Institute, The Royal Children's Hospital, Parkville, Victoria, Australia; ²Department of Paediatrics, The Royal Children's Hospital, The University of Melbourne, Parkville, Victoria, Australia; ³Children's Cancer Centre, The Royal Children's Hospital, Parkville, Victoria, Australia. Correspondence: David A. Elliott (david.elliott@mcri.edu.au)

[†]Contributed equally.

Received August 20, 2018; accepted November 8, 2018; advance online publication 11 January 2019. doi:10.1002/cpt.1311




Figure 1 Chemical structures of clinically approved anthracyclines.

hiPSC-CMs represent a novel platform for further characterization of the genetic basis of ACT, which is an area of great research interest due to its potential translation into clinical practice.

The scope of this review is to briefly discuss the current prevailing theories for the molecular mechanism of ACT, which include the inhibition of topoisomerase 2B (TOP2B), the generation of ROS, and impaired calcium handling due to the C-13 alcohol metabolites of anthracyclines. The key pharmacogenetic variants identified from pediatric cohorts to be associated with either ACT sensitivity or resistance will then be discussed in detail according to the mechanistic pathways they influence. These include DNA damage pathways, drug transport, oxidative stress defenses, iron metabolism, and sarcomere structure and function.

Genomic variants associated with ACT sensitivity and resistance in paediatric oncology cohorts

Several studies have been conducted in pediatric oncology cohorts to identify genetic variants associated with ACT (Table 1). Both candidate gene approaches and genomewide association studies (GWAS) have yielded significant single nucleotide polymorphisms (SNPs) in 18 genes, which are discussed herein. Identified genetic variants associated with ACT have roles in DNA damage pathways, drug transport, oxidative stress defenses, iron metabolism, and sarcomere structure and function, as summarized in Figure 2. To date, the genetic studies presented are limited by small sample sizes, and follow-up studies aimed at functional validation of reported gene associations are only beginning to emerge.¹⁶ Importantly, among all the studies identified, a consensus does not exist upon clear clinical and echocardiographic research criteria for an ACT diagnosis, which would allow more accurate comparisons to be drawn between cohorts regarding the timing of onset and severity of ACT.

DNA DAMAGE

DNA topoisomerase I (TOP1) and II (TOP2) relieve tension in overwound DNA by introducing transient single-stranded or double-stranded DNA breaks, respectively. Anthracyclines target and stabilize the intermediate TOP2-cleaved DNA complex, preventing reannealing and causing an accumulation of double-stranded DNA breaks¹⁷ leading to activation of DNA damage pathways ultimately resulting in programmed cell death. Two isoenzymes of TOP2 exist in mammals and both interact with anthracyclines. *TOP2A* is overexpressed in tumor cells and proposed to mediate the antineoplastic effects of anthracyclines; however, it is not expressed in the adult heart. *TOP2B* is expressed ubiquitously and has been implicated in the mechanism for the cardiotoxic effects of anthracyclines. Selective deletion of *TOP2B* from cardiomyocytes protects mice from doxorubicin-induced heart failure.¹⁸ In addition, clustered regularly interspaced short palindromic repeats and associated protein 9 (CRISPR/Cas9) disruption of *TOP2B* from human embryonic stem cell-derived cardiomyocytes reduces the levels of doxorubicin-induced double-stranded DNA breaks and cell death.¹⁹

Further support for the role of TOP2B in ACT comes from studies using dexrazoxane, a clinically used cardioprotective agent that inhibits the catalytic activity of TOP2B and reduces ROS production by chelating iron. Preincubation with dexrazoxane prior to doxorubicin exposure reduced expression of phosphorylated H2A histone, a DNA damage signal, in rat cardiomyocytes.²⁰ Furthermore, dexrazoxane protects neonatal ventricular cardiomyocytes from doxorubicin and daunorubicin-induced cytotoxicity, as measured by lactate dehydrogenase levels.²¹ Dexrazoxane did not protect neonatal ventricular cardiomyocytes from oxidative stress-induced cytotoxicity suggesting its actions to reduce ROS are not

Table 1 Studies identifying genetic variants associated with ACT in pediatric cancer cohorts according to proposed mechanistic pathway

Authors	Year	Cohort (n)	Cases (n)	Controls (n)	Study approach	Genes with significant SNPs	SNP affect upon ACT
A. DNA damage							
Aminkeng <i>et al.</i>	2015	280	32	248	GWAS	<i>RARG</i> rs2229774	Sensitizing
		96	22	74			
		80	19	61			
B. Anthracycline metabolism and transport							
Visscher <i>et al.</i>	2012	156	38	118	SNP array	<i>SLC28A3</i> rs78537585	Protective
		188	40	148			
		96	43	53			
Visscher <i>et al.</i>	2013	177	46	131	SNP array	<i>SLC28A3</i> rs78537585 <i>UGT1A6</i> rs17863783 <i>SULT2B1</i> rs10426377	Protective Sensitizing Sensitizing
Semsei <i>et al.</i>	2012	234	-	-	Candidate gene approach	<i>ABCC1</i> rs3743527, rs246221, rs3743527	Sensitizing
Armenian <i>et al.</i>	2013	255	77	178	SNP array	<i>ABCC2</i> rs8187710 <i>RAC2</i> rs1305833** <i>HFE</i> rs1799945**	Sensitizing Sensitizing Sensitizing
C. Oxidative stress capacity							
Krajinovic <i>et al.</i>	2016	251	-	-	GWAS	<i>ABCC5</i> rs7627754 <i>NOS3</i> rs1799983	Sensitizing Protective
Blanco <i>et al.</i>	2012	487	170	317	Candidate gene approach	<i>CBR3</i> rs1056892	Sensitizing
Ruiz-Pinto <i>et al.</i>	2017	93	58	35	SNP array	<i>GPR35</i> rs12468485	Sensitizing
Wang <i>et al.</i>	2014	287	93	194	SNP array	<i>HAS3</i> rs2232228	Sensitizing
Windsor <i>et al.</i>	2012	58	41	17	Candidate gene approach	<i>GSTP1</i> rs1695	Sensitizing
Rajić <i>et al.</i>	2009	76	43	33	Candidate gene approach	<i>CAT</i> rs10836235	Protective
Hildebrandt <i>et al.</i>	2017	108	46	62	Candidate gene approach	<i>PLCE1</i> rs932764 <i>ATP2B1</i> rs17249754	Protective Protective
D. Impaired iron metabolism							
Lipshultz <i>et al.</i>	2013	184	-	-	Candidate gene approach	<i>HFE</i> rs1800562	Sensitizing
E. Sarcomere dysfunction							
Wang <i>et al.</i>	2016	331	112	219	GWAS	<i>CELF4</i> rs1786814	Sensitizing
		54	54	0			

The *RAC2* and *HFE* variants identified in Armenians' study are proposed to mediate ACT through mechanisms involving reactive oxygen species and impaired iron metabolism, respectively. Variant identification and sequence references all obtained from <https://varsome.com>.

ACT, anthracycline-induced cardiotoxicity; ATP, adenosine-5'-triphosphate; CAT, cationic amino acid transporter; CBR, carbonyl reductase; CELF, CUGBP Elav-like family member; GPR, G-protein-coupled receptor; GST, glutathione s-transferase; GWAS, genomewide association study; HAS, hyaluronan synthase; NOS, nitric oxide synthase; PLCE, phospholipase C epsilon; *RARG*, retinoic acid receptor-gamma; *SLC*, solute carrier; SNP, single nucleotide polymorphism; *SULT*, sulfoltransferase; *UGT*, UDP-glucuronosyltransferase.

essential to its cardioprotective function. In contrast, dexrazoxane did not improve hiPSC-CM viability following doxorubicin exposure.¹⁵ However, the antioxidant *N*-acetyl-L-cysteine was shown to protect hiPSC-CMs, which would indicate ROS-based toxicity does contribute to ACT.

RARG variant results in sensitivity to ACT

A GWAS conducted in 280 pediatric oncology patients and replicated in two further independent cohorts of 96 and 80 patients identified SNP rs2229774 in *RARG* to be strongly associated with ACT ($P = 5.9 \times 10^{-8}$; odds ratio (OR): 4.7).¹¹ *RARG* binds

DNA regulatory sequences called retinoic acid receptor elements (RAREs) and regulates downstream gene expression in response to its agonist all-*trans* retinoic acid. Luciferase reporter assays in HEK293T cells showed *RARG* rs2229774 (p.Ser427Leu) reduced expression of a RARE reporter gene compared to wild-type *RARG*, suggesting that deregulated expression of a downstream gene could contribute to ACT. *RARG* is known to bind the TOP2B promoter. Rat cardiomyocytes (H9c2 cells) expressing *RARG* rs2229774 (p.Ser427Leu) do not repress TOP2B expression to the extent that wild-type *RARG* does. This suggests that in cardiomyocytes with the *RARG* rs2229774 (p.Ser427Leu)

variant, higher levels of TOP2B are present, which leads to a greater accumulation of DNA damage and subsequent cardiomyocyte death when anthracyclines are present.

ANTHRACYCLINE METABOLISM AND TRANSPORT

An alternative hypothesis for the mechanism of ACT involves the C-13 alcohol metabolites of anthracyclines. Carbonyl reductases convert doxorubicin to doxorubicinol, and the accumulation of doxorubicinol in cardiomyocytes is associated with impaired cardiac relaxation.²² With increasing amounts of doxorubicinol there are also greater amounts of cellular injury and cardiomyocyte death.²³ Doxorubicinol is able to directly modulate the calcium handling mechanisms of cardiomyocytes. It binds and inhibits both the Ca^{2+} -ATPase (SERCA2A) and the Ryanodine receptor (RyR2), which replenish the sarcoplasmic reticulum calcium stores and enable sarcoplasmic reticulum calcium release, respectively.²⁴ This results in impaired cardiomyocyte contraction through reduced calcium release into the cytosol. Furthermore, doxorubicinol can bind and inhibit the F_1F_0 proton pump, leading to reduced energy production that fails to meet the high-energy requirements of cardiomyocytes. Heart-specific overexpression of carbonyl reductases in mice results in the accelerated development of acute and chronic forms of ACT due to increased doxorubicinol levels.²⁵ To further support a role for the carbonyl reductases in the mechanism of ACT, a polymorphism in carbonyl reductase 3 (*CBR3*) rs1056892, which results in p.Val244Met, was identified to be associated with a significant increase in the risk of cardiomyopathy following exposure to low doses of anthracyclines in children with cancer.¹⁴

CBR3 polymorphism predisposes to the development of ACT

Carbonyl reductases metabolize anthracyclines to their toxic C-13 alcohol metabolites. SNPs in *CBR1* rs894010988 (c.*246G>A; within 3'UTR) and rs1056892 in *CBR3* (p.Val244Met) are known to affect their catalytic activity and, therefore, the metabolism of anthracyclines. Genotyping a case-controlled cohort of childhood cancer survivors ($n = 30$ cases, $n = 115$ controls) for *CBR3* rs1056892 (p.Val244Met) indicated a trend toward significance for an association with ACT ($P = 0.056$). Furthermore, recombinant CBR3V244 produced 2.6-fold greater amounts of toxic metabolite doxorubicinol compared to *CBR3*M244.²⁶ In a replicate study, in a larger cohort ($n = 170$ cases, $n = 317$ controls) for ACT-associated SNPs in CBRs, no significant association was determined for *CBR1*.²⁶ However, the homozygous G genotype at polymorphism rs1056892 in *CBR3* (p.Val244) was found to correlate with a 3.3-fold increased risk of cardiomyopathy following exposure to anthracyclines ($1\text{--}250\text{ mg/m}^2$) compared with those with a GA or AA genotype.¹⁴


SLC28A3 variant confers resistance to ACT, whereas *UGT1A6* variant predisposes to ACT

SLC28A3 encodes a sodium-coupled nucleoside transporter that is expressed in the human heart. It is able to carry both purines and pyrimidines, as well as drugs, including anthracyclines. A study of

2,977 SNPs in 220 genes involved in drug metabolism compared the genetic profiles of children who developed ACT ($n = 38$ cases) with those who did not ($n = 118$ controls) following treatment with anthracyclines using a customized Illumina GoldenGate array.²⁷ A synonymous variant of *SLC28A3*, rs78537585, (which results in a different codon encoding amino acid 461 in *SLC28A3*, i.e., p.Leu461Leu) was strongly associated with resistance to ACT ($P = 1.8 \times 10^{-5}$; OR: 0.35). The identification of this variant has been replicated in two further independent paediatric cohorts from Canada ($n = 188$) and The Netherlands ($n = 96$). Although a mechanism for *SLC28A3* protecting against ACT was not proposed, by describing its activity in transporting anthracyclines, the suggestion is that a variant may reduce the uptake of anthracycline into cardiomyocytes. However, given the variant is synonymous and does not alter the structure of the transporter it is also unlikely to change its activity. Nevertheless, a strength of this study is the endeavor to generate a risk-stratification model: high, intermediate, and low risk for predicting ACT according to a genetic profile of several genes. Combining genetic risk factors with clinical risk factors was superior to predicting ACT than either set of factors alone. In 2013, Visscher and colleagues²⁷ were able to reproduce their findings in a third independent cohort of children. The association between ACT and the *SLC28A3* variant remains to be validated in functional assays. In this study, however, a previously identified variant in UDP-glucuronyl transferase (*UGT1A6*) was found to be significant for an association with ACT ($P = 6.2 \times 10^{-3}$; OR: 7.98) *UGT1A6* glucuronidates various substrates, including anthracycline metabolites. It is speculated that altered activity in the variant rs17863783 *UGT1A6* (which is a synonymous variant; i.e., p.Val209Val) may lead to an accumulation of toxic anthracycline metabolites, which predispose to ACT. However, synonymous variants do not alter proteins structure and are, therefore, unlikely to change function. Furthermore, *SLC28A3* is not expressed in human cardiac or liver tissues, whereas *UGT1A6* is found in the liver and may result in impaired anthracycline metabolism. Nevertheless, the functional consequences of these genetic associations are difficult to discern.

ABCC1, *ABCC2*, and *ABCC5* polymorphisms sensitize to ACT

ATP-binding cassette proteins are membrane-bound transporters involved in xenobiotic clearance from cells using energy derived from ATP hydrolysis. Their substrates include numerous chemotherapeutic agents, including anthracyclines.²⁸ *ABCC1* (ATP-binding cassette, subfamily C, member 1) is highly expressed in the human heart, and mouse studies have revealed its expression levels are upregulated in the heart following exposure to doxorubicin.²⁹ Several SNPs are known to modulate the activity of *ABCC1* and, therefore, potentially influence the ability of cardiomyocytes to clear anthracyclines and limit oxidative stress. A cohort of pediatric patients ($n = 234$) diagnosed with acute lymphoblastic leukemia (ALL) were genotyped for nine SNPs in *ABCC1*.³⁰ The TT genotype at SNP rs3743527 (3'UTR; c.*543C>T) and its combination with either the TT or TC genotype at SNP rs246221 (synonymous variant, p.Val275Val) were significantly associated with a decreased left ventricular fractional shortening, as measured by echocardiography,



following treatment with anthracycline.³⁰ SNP rs246221 is a synonymous variant in *ABCC1* (p.Val275Val) and, therefore, does not alter its structure, which decreases the likelihood of

it having an effect on the activity of the transporter. In comparison, SNP rs3743527 occurs within the 3'UTR of *ABCC1* mRNA and perhaps exerts its influence by decreasing gene

Figure 2 Summary of proposed mechanisms for identified genetic variants associated with anthracycline-induced cardiotoxicity (ACT) in children. **1.** The retinoic acid receptor-gamma (*RARG*) variant decreases repression of topoisomerase (*TOP*)2*B* such that its levels increase enabling greater amounts of doxorubicin to stabilize its complex with double-stranded DNA breaks. This leads to increased DNA damage and signals for apoptosis. **2.** Carbonyl reductase (*CBR*)3 variants with increased catalytic activity result in accumulation of toxic C-13 alcohol metabolites. **3.** Decreased anthracycline uptake into cardiomyocytes due to a variant in transporter solute carrier (*SLC*)28A3 is protective against ACT. **4.** The UDP-glucuronosyltransferase (*UGT*)1A6 variant increases glucuronidation of anthracyclines resulting in higher levels of toxic metabolites, which predispose patients to ACT. **5.** Decreased anthracycline efflux due to polymorphisms in ABC transporters leads to an accumulation of anthracyclines in cardiomyocytes sensitizing them to ACT. **6.** Sulfotransferase (*SULT*)2*B*1 variant increases sulfonation and therefore renal excretion of anthracyclines and are thus protective against ACT. **7.** Mutations in the *RAC*2 subunit of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase result in increased reactive oxygen species (ROS), which predisposes to ACT. **8.** Nitric oxide synthase (*NOS*)3 variant decreases production of nitric oxide (NO) and consequential reactive nitrogen species (RNS), which culminates in resistance to ACT. **9.** A variant resulting in increased cationic amino acid transporter (*CAT*) expression protects against ACT as hydrogen peroxide is diverted away from conversion to the hydroxyl radical. **10.** Conversely, variation causing decreased activity of glutathione s-transferase p (*GSTP*)1 results in reduced protection against ROS and therefore increased susceptibility to ACT. **11.** A variant in G-protein-coupled receptor (*GPR*)35 has been associated with decreased cell viability upon exposure to anthracyclines. **12.** Decreased production of hyaluronan, an antioxidant, due to a polymorphism in hyaluronan synthase (*HAS*)3 predisposes toward ACT via increased ROS. **13.** The phospholipase C epsilon (*PLCE*)1 variant protects against ACT by reducing the oxidative stress anthracyclines cause. **14.** *HFE* mutations increasing intracellular Fe^{2+} concentration drive production of hydroxyl radicals. **15.** CUGBP Elav-like family member (*CELF*)4 variant results in the persistence of alternative splice variants of cardiac troponin T, which are developmentally inappropriate. Co expression of embryonic and adult cardiac troponin T results in a dual capacity of cardiomyocytes to respond to the increasing intracellular calcium levels that occur when anthracyclines are present. **16.** An *ATP*2*B*1 variant has been associated with ACT resistance potentially as a result of improved calcium handling that optimises sarcomere function during challenge. RARE, retinoic acid receptor element; SOD2, superoxide dismutase II.

expression levels posttranscriptionally. Polymorphisms in additional ABC transporter family members, *ABCC*2 and *ABCC*5, have also been reported. A retrospective case-controlled study identified SNP rs8187710 (p.Cys1515Tyr) in *ABCC*2 to be associated with a 4.3-fold risk of ACT ($P < 0.01$) upon genetic profiling of a mixed cohort of child and adult patients exposed to anthracyclines prior to hematopoietic cell transplant.³¹ Polymorphisms in 16 candidate genes with roles in iron homeostasis, antioxidant stress, cardiac remodeling, and anthracycline metabolism were screened for and also identified two further SNPs with significant correlations to ACT; SNP rs1799945 (c.187C>G; p.His63Asp) in *HFE*, which is consistent with evidence discussed below and SNP rs13058338 (intronic, c.108-3812A>T) in the *RAC*2, which encodes a subunit of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase. Furthermore, *ABCC*5 has been implicated in ACT with the TT genotype at SNP rs7627754 (in promoter region) being associated with reduced ejection fraction and fractional shortening.¹²

Sulfotransferase family cytosolic member 2B1 is sensitizing to ACT

Sulfotransferase family cytosolic member 2B1 (*SULT*2*B*1) is an enzyme that conjugates sulfate groups to drugs, increasing solubility in water and promoting renal excretion. The *SULT*2*B*1 variant rs10426377 (intronic c.423 + 1540C>A) was initially identified as having a weak association with ACT in pediatric patients.¹³ However, only upon replication in a second study did the association with ACT reach significance ($P = 0.054$).²⁷ Interestingly, when stratified by sex, this *SULT*2*B*1 variant only exerted a sensitizing effect in men and not women.²⁷ It is possible the *SULT*2*B*1 variant may result in a loss of catalytic function preventing anthracycline metabolites from becoming sulfonated and renally excreted. Anthracycline metabolite levels would, therefore, accumulate and be able to mediate their toxic effects for greater periods of time. However, additional work is

required to establish if the variant rs10426377 alters *SULT*2*B*1 expression levels. Furthermore, it is important to note that *SULT*2*B*1 is not highly expressed in human cardiac tissue and, therefore, would mediate its effect upon ACT indirectly.

OXIDATIVE STRESS CAPACITY

The cardiotoxic effects of anthracyclines have also been attributed to their ability to induce oxidative stress. Cardiomyocytes are particularly vulnerable to ROS-induced damage having poorer antioxidant defenses compared with hepatocytes.³² Anthracyclines generate ROS by two mechanisms: an enzymatic pathway involving the electron transport chain of mitochondria³³ and a nonenzymatic pathway involving redox cycling of iron-anthracycline complexes.³⁴ Both result in the formation of superoxide anions ($O_2^{\bullet-}$), which can either directly cause subcellular damage or become converted to the highly reactive hydroxyl radical ($\bullet OH$) via a series of reactions with superoxide dismutase and further reduction by Fe^{2+} shown in **Figure 3**.³⁵ Superoxide anions and hydroxyl radicals cause lipid peroxidation of cardiomyocyte membranes resulting in disruption of membrane integrity allowing intracellular proteins, including lactate dehydrogenase and cardiac troponin to be released.³⁶ Detailed examination of anthracycline-induced cellular morphology changes in cardiomyocytes by electron microscopy of endomyocardial biopsies demonstrated that myocyte vacuolization and myofibrillar lysis are the characteristic morphological features of ACT.^{37,38}

The role of cardiolipin and NADPH oxidase in ACT

Cardiolipin is a phospholipid enriched in the inner mitochondrial membrane for which anthracyclines have a high affinity.³³ Being lipophilic molecules, anthracyclines are able to diffuse passively across cell membranes and into mitochondria. Once bound to cardiolipin, anthracycline is reduced from its quinone form to a semiquinone by nicotinamide adenine dinucleotide. The anthracycline semiquinone then converts back to its quinone form by transferring the electron to an oxygen molecule and forming




Figure 3 Superoxide anion conversion pathway to hydroxyl radical and catalase defense pathway.

a superoxide anion.²² Thus, the electron transport chain is short-circuited and ROS are generated. Alternatively, the NADPH oxidase complex has also been implicated in the mechanism of ACT. It is expressed in cardiomyocyte mitochondria and comprised of a catalytic core situated in the membrane with four cytosolic subunits that are recruited upon its activation. NADPH oxidase generates ROS, which are known to induce a hypertrophic response that serves as an initial compensation mechanism by the failing heart, which then becomes pathological.³⁹ The SNP rs13058338 (intronic; c.108-3812A>T) in *RAC2*, which encodes an Rho-GTPase that regulates the NADPH oxidase, has been correlated with susceptibility to ACT.³¹ It is possible this variant accelerates ROS production and drives the hypertrophic response to become pathological. Cardiac-specific *RAC1* overexpression in mice results in the development of cardiomyopathy.³⁹ Furthermore, NADPH oxidase (*NOX2*) knockout mice are protected against doxorubicin-induced heart failure.⁴⁰ Inhibitors of NADPH oxidase have also been shown to reduce the damage to cardiomyocytes upon anthracycline exposure.⁴¹

***NOS3* mutation protective against ACT**

Krajcinovic *et al.*¹² investigated the influence of polymorphisms of genes involved in doxorubicin metabolism upon late-onset ACT. A cohort of 251 children with ALL exposed to doxorubicin and monitored by echocardiography were genotyped for 33 common polymorphisms of 12 genes involved in drug metabolism. Nitric oxide synthase (*NOS3*) variant rs1799983 (p.Asp298Glu) was identified to have a protective effect upon the ejection fraction (EF) of high-risk patients. The variant is known to decrease endothelial nitric oxide (NO) production. Anthracyclines are able to bind *NOS3* and inhibit its activity, thus reducing the amount of vasodilator NO produced; excess levels of NO increase the generation of reactive nitrogen species. Expediting the decomposition of the reactive nitrogen species using a catalyst has been shown to reduce doxorubicin-induced cardiomyocyte injury and cell death.⁴² The *NOS3*^{-/-} mice are protected against cardiotoxicity following doxorubicin exposure compared with mice with cardiomyocyte-specific overexpression of wild-type *NOS3*, which were shown to be more sensitive to injury and cell death.⁴³ Taking together the above studies, *NOS3* has been implicated in the pathogenesis of ACT.

Catalase variant protects against ACT, whereas *GSTP1* variant increases susceptibility

Variants inhibiting the activity of enzymes involved in oxidative stress are candidates for an association with ACT because ROS generation is a well-described potential theory for its pathogenesis. During oxidative stress, superoxide dismutase II (*SOD2*) converts superoxide to hydrogen peroxide, catalase (*CAT*) converts hydrogen peroxide to water, which prevents its reduction by Fe^{2+} to the damaging hydroxyl radical (Figure 2). Glutathione-S-transferase θ and μ (*GSTT1* and *GSTM1*) conjugate free glutathione to drug metabolites, including chemotherapeutics to prevent their damaging interactions with lipids, protein, and DNA. A cohort of childhood cancer survivors ($n = 76$) diagnosed with ALL had their genotypes at known inactivating SNPs in *SOD2*, *CAT*, *GSTT1*, and *GSTM1* determined from archived bone marrow smears. The homozygous CC allele for SNP rs10836235 (intronic, c.66 + 78C>G) in *CAT* reached statistical significance ($P = 0.02$) for an association with resistance to ACT.⁴⁴ Rajić *et al.*⁴⁴ speculate that this SNP in intron 1 interferes with binding of AP-2, a negative regulator of *CAT* transcription and, therefore, there are higher levels of *CAT* expressed in these patients protecting them from ROS and subsequent ACT. No variants from the other genes were found to have significant associations with ACT. However, a variant in *GSTP1* rs1695 (c.313A>G; Ile105Val) was associated with cardiotoxicity ($P = 0.008$) in a cohort of children ($n = 60$) treated with doxorubicin for osteosarcoma.⁴⁵ Already vulnerable to oxidative stress, cardiomyocytes are proposed to be rendered further unprotected from ROS in patients with reduced activity of *GSTP1*. In this retrospective study, an initial drop in EF on echocardiography from that recorded at diagnosis was seen in 16 patients (29%) and considered to represent early ACT. By the end of treatment, 25 patients (45%) had decreased cardiac EF. The need for future prospective studies monitoring the EF throughout treatment in large cohorts is highlighted by this study as well as the need to validate gene associations with ACT.

***GPR35* missense mutation increases susceptibility to and severity of ACT**

The genetic association studies discussed so far have focused on common SNPs with a minor allele frequency (MAF) > 5%. Alternatively, Ruiz-Pinto *et al.*⁴⁶ hypothesize that low frequency alleles (MAF < 5%) also have a role to play in complex pathophysiological processes, such as ACT. An Illumina HumanExome BeadChip array, enriched for low-frequency alleles (MAF < 1%) was used to profile case-control matched pediatric patients with cancer ($n = 35$ cases, $n = 58$ controls). Cases of ACT were defined as chronic ACT if the onset occurred > 1 year following anthracycline treatment. Upon gene-based testing, as opposed to single-variant testing performed in other studies, G-protein coupled receptor 35 (*GPR35*) was detected to have a significant association with chronic ACT.⁴⁶ The missense mutation rs12468485 in *GPR35* (c.758C>T p.T253M) carried the strongest association with chronic ACT, and the T allele conferred increased risk of chronic ACT and increased severity of ACT at low doses of anthracycline. *GPR35* has been found to be upregulated in patients with severe congestive heart failure.⁴⁷ An *in vitro* study has shown

its expression levels in cardiomyocytes are exquisitely sensitive to hypoxic conditions upon which they are upregulated. In turn, overexpression of GPR35 in cardiomyocytes results in reduced cell viability.⁴⁸ It is possible that the ROS generated by anthracyclines mimic the hypoxic conditions in the failing heart, leading to increased GPR35 expression, which is correlated with reduced cell viability. Functional validation of the observed genotype-phenotype associations have yet to be performed.

Hyaluronan synthase-3 variant modifies risk of developing ACT

Hyaluronan is a glycosaminoglycan found in the extracellular matrix. It is synthesized by hyaluronan synthase-3 (*HAS3*) and forms polymers that are known to serve as scaffolds during tissue remodeling following injury. Wang *et al.*⁴⁹ identified an SNP rs2232228 (synonymous variant; p.Ala93Ala) in *HAS3* to be associated with altering the risk of developing ACT. An SNP array (ITMAT/Broad CARE) of 34,912 common variants in 2,100 genes associated with cardiovascular disease was used to profile a case-controlled cohort of childhood cancer survivors with and without cardiomyopathy postanthracycline exposure ($n = 93$ cases, $n = 194$ controls). Patients with the AA genotype in SNP rs2232228 *HAS3* exposed to high doses of anthracycline > 250 mg/m² were at 8.9-fold greater risk of developing ACT compared with those with the GG genotype.⁴⁹ This dose-dependent increase in the risk of developing ACT among patients with the AA genotype was reproduced in an independent replication cohort of patients ($n = 76$) with diagnosed ACT. Given hyaluronan has antioxidant properties, it is suggested that patients with the AA genotype in *HAS3* have decreased production of hyaluronan leaving them susceptible to ROS-induced damage generated by anthracyclines. In addition, hyaluronan has been found to promote rat cardiomyocyte survival during ROS damage by directly binding its receptor CD44 and stimulating cell proliferation.⁵⁰ Given rs2232228 does not change the protein sequence, one proposed mechanism was that the cardiac *HAS3* expression levels of the AA genotype would be lower; however, no statistically significant difference between genotypes was observed.⁴⁹ Thus, the mechanistic basis by which this synonymous variant leads to ACT remains to be discovered.

Phospholipase C ϵ variants confers protection against ACT

Long-term survivors of childhood cancer with hypertension have an increased risk of developing ACT. It is possible the increased workload on the heart due to hypertension exacerbates any underlying, perhaps asymptomatic, dysfunction to produce symptomatic ACT. Genetic analysis of 108 childhood cancer survivors was performed for a panel of 12 known hypertension susceptibility loci.⁵¹ Two variants, *PLCE1* rs932764 (intronic variant; c.1492 + 3724A>G) and *ATP2B1* rs17249754 (discussed in E. Sarcomere dysfunction; intronic variant; c.-221-10702C>T) were associated with protection against the development of ACT, and both are expressed in human cardiac tissue.⁵¹ Phospholipase C ϵ (*PLCE1*) is a second messenger, able to induce Ca²⁺ signalling and activate protein kinase C and D. Using hiPSC-CMs that were exposed to doxorubicin for 48 hours, expression of *PLCE1* was found to be downregulated. *PLCE1* is known to reduce ROS generation through the activation of protein

kinase D. Therefore, this *PLCE1* variant potentially protects against the development of ACT by having increased capacity to mitigate the toxic effects of ROS. *PLCE1*-deficient mice have decreased cardiac function following exposure to hypertrophic stress signals both acutely and chronically.⁵²

IMPAIRED IRON METABOLISM

***HFE* deficiency increases sensitivity to ACT**

Given iron chelators such as dexrazoxane have cardioprotective effects, it was hypothesized by Miranda *et al.*⁵³ that genes responsible for hereditary hemochromatosis, a condition marked by iron overload, could play a role in sensitizing patients to ACT. In their study, *HFE*^{-/-} mice and wild-type mice ($n = 7$) were treated with intraperitoneal injections of doxorubicin (20 mg/kg) and the *HFE*-deficient mice were found at day 4 posttreatment to have higher levels of serum creatine kinase, a biomarker of cardiac damage compared to wild-type mice.⁵³ This study generated interest for profiling childhood cancer survivors for the two SNPs in *HFE* rs1800562 (p.C282Y) and rs1799945 (p.H63D) that are linked to hereditary haemochromatosis. *HFE* encodes a major histocompatibility complex class 1–like protein that is able to bind transferrin, an iron transport molecule, and regulate the production of the master regulator of iron storage, hepcidin. Lipshultz *et al.*⁵⁴ recruited 184 pediatric patients with cancer between 2005 and 2007 and identified their genotype at the above two SNPs in *HFE*. Of this cohort, 10% carried the SNP rs1800562 (p.C282Y) and the heterozygous rs1800562 (p.C282Y) genotype correlated with multiple increases in serum cardiac troponin T during chemotherapy and reduced left ventricular function on echocardiography at 2.2-year follow-up. These findings suggest that carriers of *HFE* SNPs are more sensitive to developing ACT and would potentially benefit from receiving iron chelation therapy with dexrazoxane prior to commencing treatment. Although Lipshultz *et al.*⁵⁴ suggest *HFE* genotyping prior to anthracycline exposure, there are implications for patients and their families with regard to the rare finding of a homozygous.

SARCOMERE DYSFUNCTION

CUGBP Elav-like family member-4 variant modifies risk of developing ACT

In a follow-up study, Wang *et al.*⁵⁵ identified an SNP in CUGBP Elav-like family member 4 (*CELF4*) associated with altering the risk of developing ACT. *CELF4* is an RNA binding protein involved in tissue-specific, developmentally regulated pre-mRNA splicing. It is known to mediate the alternative splicing of the gene *TNNT2*, which encodes cardiac troponin T, a component of thin filaments in sarcomeres. Splice variants of cardiac troponin T bearing an alternative exon 5 are predominately expressed in the embryonic heart and significantly downregulated during development into the adult heart.⁵⁶ *CELF4* variants with reduced activity to target *TNNT2* pre-mRNA enable the continued expression of embryonic cardiac troponin T in the adult heart. This results in a dual capacity for thin myofilaments to handle increasing calcium concentrations and potentially compromises their contractility and ultimately left ventricular ejection fraction. In favor of this proposed mechanism are findings of multiple *TNNT2* splice

variants present in patients with cardiomyopathies.⁵⁷ In contrast to their previous approach using an SNP array of common variants associated with cardiovascular disease, Wang *et al.*⁵⁵ used a case-controlled GWAS performed in childhood cancer survivors comparing those who had developed cardiomyopathy postanthracycline with healthy controls ($n = 112$ cases, $n = 219$ controls) and identified an association with SNP rs1786814 (intronic, c.287-11458C>T) in *CELF4*. Patients exposed to doses of anthracycline > 300 mg/m² with the CC genotype (publication 55 used nomenclature GG, GA, and AA) had a 10.2-fold increased risk of developing ACT. However, the CT and TT genotypes for *CELF4* rs1786814 mitigated the risk of ACT. These findings were repeated in an independent replication cohort ($n = 54$) of childhood cancer survivors with cardiomyopathy. To examine whether the high-risk CC genotype for the *CELF4* SNP was associated with the co-expression of multiple *TNNT2* splice variants, DNA was isolated from 33 healthy heart samples. The CC genotype was detected in 21 of 33 samples with embryonic and adult *TNNT2* splice variants being found more commonly in these samples.

ATP2B1 variant confers protection against ACT

ATP2B1 encodes a plasma membrane ATPase, which is the calcium pump responsible for maintaining low cytosolic calcium during cardiomyocyte relaxation. SNP rs17249754 (intronic; c.-221-10702C>T) in *ATP2B1* confers resistance to ACT.⁵¹ Following doxorubicin exposure, hiPSC-CMs had increased expression levels of *ATP2B1* and were less susceptible to ACT.⁵¹ Because doxorubicin is known to impair calcium handling, expression of *ATP2B1* may become upregulated in response to rising cytosolic calcium levels and help reduce excess cytosolic calcium. Efficient cytosolic calcium clearance is necessary for sarcomere relaxation and maintenance of calcium-coupled contraction.

DISCUSSION

The advent of hiPSC-CMs has provided a relevant human cardiomyocyte model cell type in which to perform functional validation studies to demonstrate that a given genetic variant may predispose an individual to ACT (Figure 4). Importantly, functional validation studies of ACT-associated genomic variants

remain to be done. Clinical practice recommendations developed by the Canadian Pharmacogenomic Network for Drug Safety suggest pharmacogenomic testing of RARG rs2229774 (p.S427L), SLC28A3 rs7853758 (p.L461L), and UGT1A6 rs17863783 (p.V209V).⁵⁸ However, the clinical significance of the latter two variants must be interpreted with care because they are silent mutations that do not alter the protein structure or function, nor do they create alternative splice transcripts. Furthermore, SLC28A3 and UGT1A6 are not expressed in cardiac tissue, suggesting their influence is mediated through an indirect mechanism.⁵⁹ These guidelines, although published, have not been incorporated broadly into pediatric oncology practice because of the low level of evidence and lack of robust functional validation or prospective trials. Studies demonstrating the functional validity in relevant disease models, for example, patient-specific hiPSC-CMs (i.e., iPSCs from pediatric oncology patients exposed to anthracyclines that have been differentiated into cardiomyocytes), are still required in order to provide robust evidence to guide the development of genetic screening tests that are applicable to the clinic.

Broadly, however, hiPSC-CMs are a useful model to study the molecular mechanism of ACT. Holmgren *et al.*⁶⁰ examined the effect of doxorubicin on global protein expression in hiPSC-CMs and found a dose-dependent increase in the number of differentially expressed proteins that was maximal at day 14 postexposure. Interestingly, proteins involved in sarcomere function, including myosin light and heavy chains, troponins and tropomyosins were downregulated following doxorubicin treatment, which is in keeping with the reduced contractility of cardiomyocytes and a potential mechanism for ACT. Additionally, changes to gene expression following doxorubicin exposure have been identified in hiPSC-CMs using RNASeq studies.^{15,60-62} For example, genes involved in the DNA damage repair response pathway and cell cycle regulation are significantly downregulated following doxorubicin exposure.⁶¹ Furthermore, this approach has highlighted interesting linkages, such variation at rs885004 (intronic, c.862-360C>T) altering *SLC28A3* expression levels in hiPSCs.⁶²

The complex nature of the pharmacogenomics of ACT is only beginning to be unravelled and there is still much to be




Figure 4 Disease modeling anthracycline-induced cardiotoxicity (ACT) with patient-specific human-induced pluripotent stem cells-derived cardiomyocytes (hiPSC-CMs).

determined. Current knowledge implicates TOP2B inhibition, ROS generation, and the C-13 anthracycline alcohol metabolites in the development of ACT. The GWAS and candidate gene approach studies to date, to determine genomic variants associated with ACT, have been relatively underpowered and await further independent replication studies to confirm the original findings. However, the recent advent of rapid hiPSC-CM generation from larger cohorts provides a tool to further dissect the molecular response to anthracycline to identify quantitative trait loci associated with ACT.⁶² Functional validation of identified genetic variants will improve our understanding of how identified variants contribute to ACT susceptibility. The hiPSC-CMs generated from ACT-sensitive and ACT-resistant pediatric oncology patients provide an experimentally tractable human model system¹⁵ to validate genetic variants and further characterize the molecular mechanisms of ACT. These studies will inform the incorporation of genetic screening for ACT sensitivity into clinical practice.

FUNDING

No funding was received for this work.

CONFLICT OF INTEREST

The authors declared no competing interests for this work.

© 2018 Murdoch Childrens Research Institute. Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology and Therapeutics

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

- Miller, K. *et al.* Cancer treatment and survivorship statistics, 2016. *CA Cancer J. Clin.* **66**, 271–289 (2016).
- Australian Childhood Cancer Registry. A summary of childhood cancer statistics 1983–2014. Queensland: Cancer Council (2014). <<https://cancerqld.blob.core.windows.net/site/content/uploads/2017/12/A-summary-of-childhood-cancer-in-Australia-1983-2014.pdf>>. Accessed February 27, 2018.
- Smith, L. *et al.* Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. *BMC Cancer* **10**, 1–14 (2010).
- Minotti, G., Menna, P., Salvatorelli, E., Cairo, G. & Gianni, L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. *Pharmacol. Rev.* **56**, 185–229 (2004).
- Jain, K. *et al.* A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. *J. Clin. Oncol.* **3**, 818–826 (1985).
- Van der Pal, H. *et al.* Cardiac function in 5-year survivors of childhood cancer a long-term follow-up study. *Arch. Intern. Med.* **170**, 1247–1255 (2010).
- Lipshultz, S., Alvarez, J. & Scully, R. Anthracycline associated cardiotoxicity in survivors of childhood cancer. *Heart* **94**, 525–533 (2008).
- Van Dalen, E., van der Pal, H., Kok, W., Caron, H. & Kremer, L. Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study. *Eur. J. Cancer* **42**, 3191–3198 (2006).
- Felker, G.M. *et al.* Underlying causes and long term survival in patients with initially unexplained cardiomyopathy. *N. Engl. J. Med.* **342**, 1077–1084 (2000).
- Mulrooney, D.A. *et al.* Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. *BMJ* **339**, b4606 (2009).
- Aminkeng, F. *et al.* A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer. *Nat. Genet.* **47**, 1079–1084 (2015).
- Krajcinovic, M. *et al.* Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia. *Pharmacogenomics J.* **16**, 530–535 (2016).
- Visscher, H. *et al.* Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. *J. Clin. Oncol.* **30**, 1422–1428 (2012).
- Blanco, J. *et al.* Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes—a report from the Children’s Oncology Group. *J. Clin. Oncol.* **30**, 1415–1421 (2011).
- Burridge, P.W. *et al.* Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. *Nat. Med.* **22**, 547–556 (2016).
- Linschoten, M., Teske, A.J., Cramer, M.J., van der Wall, E. & Asselbergs, F.W. Chemotherapy-related cardiac dysfunction: a systematic review of genetic variants modulating individual risk. *Circ. Genom. Precis. Med.* **11**, e001753 (2018).
- Tewey, K.M., Rowe, T.C., Yang, L., Halligan, B.D. & Liu, L.F. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. *Science* **226**, 466 (1984).
- Zhang, S. *et al.* Identification of the molecular basis of doxorubicin-induced cardiotoxicity. *Nat. Med.* **18**, 1639–1642 (2012).
- Maillet, A. *et al.* Modeling doxorubicin-induced cardiotoxicity in human pluripotent stem cell derived-cardiomyocytes. *Sci. Rep.* **6**, srep25333 (2016).
- Lyu, Y.L. *et al.* Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. *Cancer Res.* **67**, 8839–8846 (2007).
- Vavrova, A. *et al.* Catalytic inhibitors of topoisomerase II differentially modulate the toxicity of anthracyclines in cardiac and cancer cells. *PLoS One* **8**, e76676 (2013).
- Mordente, A., Meucci, E., Martorana, G., Giardina, B. & Minotti, G. Human heart cytosolic reductases and anthracycline cardiotoxicity. *IUBMB Life* **52**, 83–88 (2001).
- Mushlin, P., Cusack, B., Boucek, R., Andrejok, T., Li, X. & Olson, R. Time-related increases in cardiac concentrations of doxorubicin could interact with doxorubicin to depress myocardial contractile function. *Br. J. Pharmacol.* **110**, 975–982 (1993).
- Hanna, A., Lam, A., Tham, S., Dulhunty, A. & Beard, N. Adverse effects of doxorubicin and its metabolic product on cardiac RyR2 and SERCA2A. *Mol. Pharmacol.* **86**, 438–449 (2014).
- Forrest, G.L., Gonzalez, B., Tseng, W., Li, X. & Mann, J. Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice. *Cancer Res.* **60**, 5158–5164 (2000).
- Blanco, J. *et al.* Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. *Cancer* **112**, 2789–2795 (2008).
- Visscher, H. *et al.* Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline induced cardiotoxicity in children. *Pediatr. Blood Cancer* **60**, 1375–1381 (2013).
- Couture, L., Nash, J. & Turgeon, J. Role of ATP-binding cassette transporters in drug distribution to the heart and protection from toxic compounds. *Heart Metab.* **35**, 1–6 (2007).
- Jungsuwadee, P. *et al.* Mrp1 localization and function in cardiac mitochondria after doxorubicin. *Mol. Pharmacol.* **75**, 111726 (2009).
- Semsei, A. *et al.* ABCC1 polymorphisms in anthracycline-induced cardiotoxicity in childhood acute lymphoblastic leukaemia. *Cell Biol. Int.* **36**, 79–86 (2012).

31. Armenian, S.H. *et al.* Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation. *Br. J. Haematol.* **163**, 205–213 (2013).
32. Doroshow, J., Locker, G. & Myers, C. Enzymatic defenses of the mouse heart against reactive oxygen metabolites. *J. Clin. Invest.* **65**, 128–135 (1980).
33. Goormaghtigh, E., Huart, P., Praet, M., Brasseur, R. & Ruyschaert, J.M. Structure of the Adriamycin-cardiolipin complex role in mitochondrial toxicity. *Biophys. Chem.* **35**, 247–257 (1990).
34. Gianni, L., Zweier, J., Levy, A. & Myers, C. Characterisation of the cycle of iron-mediated electron transfer from Adriamycin to oxygen. *J. Biol. Chem.* **250**, 6820–6826 (1984).
35. Horenstein, M.S., Heide, R. & L'Ecuyer, T. Molecular basis of anthracycline-induced cardiotoxicity and its prevention. *Mol. Genet. Metab.* **71**, 436–444 (2000).
36. Singal, P.K., Iliskovic, N., Li, T. & Kumar, D. Adriamycin cardiomyopathy: pathophysiology and prevention. *FASEB J.* **11**, 931–936 (1997).
37. Billingham, M., Mason, J., Bristow, M. & Daniels, J. Anthracycline cardiomyopathy monitored by morphologic changes. *Cancer Treat. Rep.* **62**, 865–872 (1978).
38. Glass, C. & Mitchell, R. Winning the battle, but losing the war: mechanisms and morphology of cancer-therapy-associated cardiovascular toxicity. *Cardiovasc. Pathol.* **30**, 55–63 (2017).
39. Akki, A., Zhang, M., Murdoch, C., Brewer, A. & Shah, A. NADPH oxidase signalling and cardiac myocyte function. *J. Mol. Cell. Cardiol.* **47**, 15–22 (2009).
40. Zhao, Y. *et al.* Nox2 NADPH oxidase promotes pathologic cardiac remodeling associated with doxorubicin chemotherapy. *Cancer Res.* **70**, 9287–9297 (2010).
41. Garner, A.P. *et al.* Nitric oxide synthases catalyse the activation of redox cycling and bioreductive anticancer agents. *Cancer Res.* **59**, 1929–19234 (1999).
42. Pacher, P. *et al.* Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. *Circulation* **107**, 896–904 (2003).
43. Neilan, T.G. *et al.* Disruption of nitric oxide synthase 3 protects against the cardiac injury, dysfunction, and mortality induced by doxorubicin. *Circulation* **2**, 506–514 (2007).
44. Rajić, V. *et al.* Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood. *Leuk. Lymphoma* **50**, 1693–1698 (2009).
45. Windsor, R., Strauss, S., Kallis, C., Wood, N. & Whelan, J. Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma. *Cancer* **118**, 1856–1867 (2012).
46. Ruiz-Pinto, S. *et al.* Exome array analysis identifies GPR35 as a novel susceptibility gene for anthracycline-induced cardiotoxicity in childhood cancer. *Pharmacogenet. Genomics* **27**, 445–453 (2017).
47. Min, K.D. *et al.* Identification of genes related to heart failure using global gene expression profiling of human failing myocardium. *Biochem. Biophys. Res. Commun.* **393**, 55–60 (2010).
48. Ronkainen, V.P. *et al.* Hypoxia inducible factor 1-induced G protein-coupled receptor 35 expression is an early marker of progressive cardiac remodelling. *Cardiovasc. Res.* **101**, 69–77 (2014).
49. Wang, X. *et al.* Hyaluronan synthase 3 variant and anthracycline-related cardiomyopathy: a report from the Children's Oncology Group. *J. Clin. Oncol.* **32**, 647–653 (2014).
50. Law, C., Li, J., Chou, H., Chen, Y. & Chan, H. Hyaluronic acid-dependent protection in H9C2 cardiomyocytes: a cell model of heart ischemia-reperfusion injury and treatment. *Toxicology* **303**, 54–71 (2013).
51. Hildebrandt, M. *et al.* Hypertension susceptibility loci are associated with anthracycline-related cardiotoxicity in long-term childhood cancer survivors. *Sci. Rep.* **7**, 9698 (2017).
52. Wang, H. *et al.* Phospholipase C epsilon modulates beta-adrenergic receptor-dependent cardiac contraction and inhibits cardiac hypertrophy. *Circ. Res.* **97**, 1305–1313 (2005).
53. Miranda, C. *et al.* HFE deficiency increases susceptibility to cardiotoxicity and exacerbates changes in iron metabolism induced by doxorubicin. *Blood* **102**, 2574–2580 (2003).
54. Lipshultz, S. *et al.* Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia. *Cancer* **119**, 3555–3562 (2013).
55. Wang, X. *et al.* CELF4 variant and anthracycline-related cardiomyopathy: a Children's Oncology Group genome-wide association study. *J. Clin. Oncol.* **34**, 863–870 (2016).
56. Cooper, T. & Ordahl, C. A single cardiac troponin T gene generates embryonic and adult isoforms via developmentally regulated alternate splicing. *J. Biol. Chem.* **260**, 11140–11148 (1985).
57. Anderson, P. *et al.* Molecular basis of human cardiac troponin T isoforms expressed in the developing, adult, and failing heart. *Circ. Res.* **76**, 681–686 (1995).
58. Aminkeng, F. *et al.* Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity. *Br. J. Clin. Pharmacol.* **82**, 683–695 (2016).
59. Craig, L., Ekert, P., Conyers, R. & Elliott, D. Genetic determinants of anthracycline cardiotoxicity – ready for the clinic? *Br. J. Clin. Pharmacol.* **83**, 1141–1142 (2017).
60. Holmgren, G., Sartipy, P., Andersson, C., Lindahl, A. & Synnergren, J. Expression profiling of human pluripotent stem cell-derived cardiomyocytes exposed to doxorubicin – integration and visualization of multi omics data. *Toxicol. Sci.* **163**, 182–195 (2018).
61. Reyes, M., Ma, J., Grove, M., Ater, J., Morrison, A. & Hildebrandt, M. RNA sequence analysis of inducible pluripotent stem cell-derived cardiomyocytes reveals altered expression of DNA damage and cell cycle genes in response to doxorubicin. *Toxicol. Appl. Pharmacol.* **356**, 44–53 (2018).
62. Knowles, D.A. *et al.* Determining the genetic basis of anthracycline-cardiotoxicity by molecular response QTL mapping in induced cardiomyocytes. *Elife* **7**, pii: e33480 (2018).